BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee C, Kim M, Han J, Yoon M, Jung Y. Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis. Biomedicines 2021;9:1598. [PMID: 34829827 DOI: 10.3390/biomedicines9111598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Han H, Jin W, Li X. Mesenchymal stem cells-based therapy in liver diseases. Mol Biomed 2022;3:23. [DOI: 10.1186/s43556-022-00088-x] [Reference Citation Analysis]
2 Zhao Y, Yu Y, Wang S, Li J, Teng L. Small extracellular vesicles encapsulating lefty1 mRNA inhibit hepatic fibrosis. Asian Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ajps.2022.07.004] [Reference Citation Analysis]
3 Shokravi S, Borisov V, Zaman BA, Niazvand F, Hazrati R, Khah MM, Thangavelu L, Marzban S, Sohrabi A, Zamani A. Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review. Stem Cell Res Ther 2022;13:192. [PMID: 35527304 DOI: 10.1186/s13287-022-02825-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Liu Q, Lv C, Huang Q, Zhao L, Sun X, Ning D, Liu J, Jiang Y, Jin S. ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway. Cell Death Discov 2022;8:51. [PMID: 35136027 DOI: 10.1038/s41420-022-00846-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]